CAHealth Canada has approved a generic version of Wegovy, a semaglutide drug used for weight loss, produced by Canadian company Apotex under the name Sevmia. This medication is considered pharmaceutically equivalent to Wegovy, manufactured by Denmark's Novo Nordisk. The approval allows Sevmia to be prescribed to individuals aged 12 and older as part of a weight management plan involving dietary changes and increased physical activity. It marks the third generic semaglutide medication approved by Health Canada, with the first two being authorized for treating Type 2 diabetes in adults. Earlier this year, generic versions of another Novo Nordisk drug, Ozempic, were approved by Indian and Canadian manufacturers. Health Canada is currently reviewing additional applications for generic semaglutide from various companies and anticipates making further decisions soon. Experts estimate that generic alternatives could significantly reduce costs compared to branded medications.
Bias read (Center): The article provides factual information about the approval of a generic drug by Health Canada, focusing on medical and pharmaceutical aspects rather than taking a stance on political issues. There is no evident framing that leans toward any particular political ideology.
Why these scores (Factual 98 · Objective 97): Highly factual with detailed information about the approval of Sevmia, its equivalence to Wegovy, and pricing expectations. The article remains largely objective, presenting facts without overt bias.
